GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Progyny Inc (NAS:PGNY) » Definitions » Net Current Asset Value

Progyny (Progyny) Net Current Asset Value : $4.54 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Progyny Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Progyny's net current asset value per share for the quarter that ended in Dec. 2023 was $4.54.

The historical rank and industry rank for Progyny's Net Current Asset Value or its related term are showing as below:

PGNY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7.06   Med: 24.08   Max: 35.62
Current: 7.17

During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of Progyny was 35.62. The lowest was 7.06. And the median was 24.08.

PGNY's Price-to-Net-Current-Asset-Value is ranked worse than
53.15% of 254 companies
in the Healthcare Providers & Services industry
Industry Median: 6.725 vs PGNY: 7.17

Progyny Net Current Asset Value Historical Data

The historical data trend for Progyny's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progyny Net Current Asset Value Chart

Progyny Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial 1.14 1.19 1.67 2.87 4.54

Progyny Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.87 3.20 3.67 4.21 4.54

Competitive Comparison of Progyny's Net Current Asset Value

For the Health Information Services subindustry, Progyny's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progyny's Price-to-Net-Current-Asset-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Progyny's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Progyny's Price-to-Net-Current-Asset-Value falls into.



Progyny Net Current Asset Value Calculation

Progyny's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(640.407-203.191-0-0)/96.3485
=4.54

Progyny's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(640.407-203.191-0-0)/96.3485
=4.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Progyny  (NAS:PGNY) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Progyny Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Progyny's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Progyny (Progyny) Business Description

Traded in Other Exchanges
N/A
Address
1359 Broadway, New York, NY, USA, 10018
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
Executives
David J Schlanger director, officer: Executive Chairman C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Michael E Sturmer officer: President 48 LEDYARD RD, WEST HARTFORD CT 06117
Mark S. Livingston officer: Chief Financial Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FL, NEW YORK NY 10018
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Peter Anevski officer: Chief Executive Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Cheryl Scott director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Norman Payson director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Allison Swartz officer: EVP, GC C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Lloyd H Dean director 185 BERRY STREET, SUITE 300, SAN FRANCISCO CA 94107
Monice Barbero officer: EVP, GC and Secretary C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Beth C Seidenberg director
Jennifer Bealer officer: EVP, General Counsel C/O PROGYNY, INC., 245 5TH AVENUE, NEW YORK NY 10016
Malissia Clinton director 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730